Аннотация
Введение. По итогам клинических исследований в мире накоплен значительный опыт применения
дерматологического индекса качества жизни (ДИКЖ). Он может оказаться полезным при предоставлении медицинской помощи пациентам с псориазом в повседневной клинической практике.
Целью исследования явился систематический анализ исключительно новых результатов (за последние 5 лет) применения ДИКЖ для оценки тяжести течения псориаза.
Материалы и методы. Развернутый поиск релевантных источников осуществлялся с использованием библиографической базы PubMed/Medline. В поисковой строке применялись ключевые слова Dermatology Life Quality Index, Psoriasis. Исключались работы, основная цель которых не касалась проблем применения ДИКЖ, а также однотипные публикации, описывающие повторяющиеся свойства и характеристики ДИКЖ.
Результаты. ДИКЖ может применяться в рамках клинических исследований, а также при анали-
зе данных в условиях реальной клинической практики. В ряде исследований ДИКЖ применяется для анализа результативности новых видов терапии. Его показатели обычно коррелируют с данными оценки по индексу площади и тяжести псориатических поражений (PASI) и результатами применения других шкал оценки качества жизни. Большая часть научных публикаций посвящена применению ДИКЖ в рамках клинических исследований, в том числе анализу эффективности биологической
терапии.
Обсуждение. Чтобы получить все доказательства целесообразности применения ДИКЖ и его мо-
дификаций в различных клинических ситуациях, можно расширить использование комплексного
подхода, основанного на одновременной комбинации различных шкал в пилотных исследованиях.
Полный текст
Список литературы
1. Rencz F, Szabó Á, Brodszky V. Questionnaire Modifications and Alternative Scoring Methods of the
Dermatology Life Quality Index: A Systematic Review. Value Heal. 2021;24(8):1158-1171. doi:https://doi.
org/10.1016/j.jval.2021.02.006
2. Ali FM, Cueva AC, Vyas J, et al. A systematic review of the use of quality of life instruments in randomized controlled trials for psoriasis. Br J Dermatol. 2017;176(3):577-593. doi:10.1111/bjd.14788
3. Basra MKA, Chowdhury MMU, Smith E V., Freemantle N, Piguet V. A Review of the Use of the Dermatology Life Quality Index as a Criterion in Clinical Guidelines and Health Technology Assessments in Psoriasis and Chronic Hand Eczema. Dermatol Clin. 2012;30(2):237-244. doi:10.1016/j.det.2011.11.002
4. Eissing L, Rustenbach SJ, Krensel M, et al. Psoriasis registries worldwide: systematic overview on registry
publications. J Eur Acad Dermatology Venereol. 2016;30(7):1100-1106. doi:10.1111/jdv.13634
5. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical
use. Clin Exp Dermatol. 1994;19(3):210-216. doi:10.1111/j.1365-2230.1994.tb01167.x
6. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatology Venereol. 2017;31(2):205-212. doi:10.1111/jdv.13854
7. Dave R, Alkeswani A. An Overview of Biologics for Psoriasis. J Drugs Dermatology. 2021;20(11):1246-1247. doi:10.36849/JDD.6040
8. Chen Y, Wei L, Song Y, et al. Life quality among psoriasis patients based on Dermatology Life Quality
Index evaluation and its association with psoriasis severity in China: a cross-sectional study. Ann Med.
2023;55(1). doi:10.1080/07853890.2023.2231847
9. Houghton K, Patil D, Gomez B, Feldman SR. Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab. Dermatol Ther (Heidelb). 2021;11(4):1373-1384. doi:10.1007/s13555-021-00564-2
10. Barbieri JS, Gelfand JM. Influence of “Not Relevant” Responses on the Dermatology Life Quality Index (DLQI) for Patients With Psoriasis in the United States. JAMA Dermatology. 2019;155(6):743. doi:10.1001/jamadermatol.2018.5655
11. Rencz F, Brodszky V, Gulácsi L, et al. Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. J Eur Acad Dermatol Venereol. 2019;33(7):e267-e269. doi:10.1111/jdv.15537
12. Langenbruch A, Radtke MA, Gutknecht M, Augustin M. Does the Dermatology Life Quality Index
(DLQI) underestimate the disease-specific burden of psoriasis patients? J Eur Acad Dermatol Venereol.
2019;33(1):123-127. doi:10.1111/jdv.15226
13. Rencz F, Gulácsi L, Péntek M, et al. Proposal of a new scoring formula for the Dermatology Life Quality
Index in psoriasis. Br J Dermatol. 2018;179(5):1102-1108. doi:10.1111/bjd.16927
14. Nasreen S, Ahmed I, Effendi S. Frequency and magnitude of anxiety and depression in patients with
psoriasis vulgaris. J Coll Physicians Surg Pak. 2008;18(7):397-400.
15. Tadros A, Vergou T, Stratigos AJ, et al. Psoriasis: is it the tip of the iceberg for the quality of life of
patients and their families? J Eur Acad Dermatology Venereol. 2011;25(11):1282-1287. doi:10.1111/j.1468-
3083.2010.03965.x
16. Khan JM, Rathore MU, Tahir M, Abbasi T. Dermatology Life Quality Index In Patients Of Psoriasis And Its Correlation With Severity Of Disease. J Ayub Med Coll Abbottabad. 2020;32(1):64-67. http://www.ncbi.nlm.nih.gov/pubmed/32468758
17. Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of
life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad
Dermatology Venereol. 2017;31(2):213-220. doi:10.1111/jdv.14007
18. Augustin M, Dauden E, Mrowietz U, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatology Venereol. 2021;35(2):431-440. doi:10.1111/jdv.16632
19. Blauvelt A, Wu J, Armstrong A, Menter A, Liu C, Jacobson A. Importance of Complete Skin Clearance
in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes. J Drugs Dermatology.
2020;19(5):487-492. doi:10.36849/JDD.2020.4957
20. Prevezas C, Katoulis AC, Papadavid E, Panagakis P, Rigopoulos D. Short-Term Correlation of the Psoriasis
Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index,
before and after Treatment, in Patients with Skin and Nail Psoriasis. Ski appendage Disord. 2019;5(6):344-
349. doi:10.1159/000499348
21. Leong WC, Tang JJ. Scalp psoriasis and Dermatology Life Quality Index: A retrospective study based on 12-year data from the Malaysian Psoriasis Registry. Malaysian Fam physician Off J Acad Fam Physicians Malaysia. 2022;17(3):84-88. doi:10.51866/oa.146
22. Liluashvili S, Kituashvili T. Dermatology Life Quality Index and disease coping strategies in psoriasis patients. Adv Dermatology Allergol. 2019;36(4):419-424. doi:10.5114/ada.2018.75810
23. Davison NJ, Thompson AJ, Turner AJ, et al. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis. Value Heal. 2018;21(8):1010-1018. doi:10.1016/j.jval.2017.10.024
24. Imafuku S, Kanai Y, Murotani K, et al. Utility of the Dermatology Life Quality Index at initiation or
switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE
study. J Dermatol Sci. 2021;101(3):185-193. doi:10.1016/j.jdermsci.2021.01.002
25. Robinson S, Moon TM, Eng TK, et al. Dermatology Life Quality Index in Patients with Psoriasis Treated
with Biologic Versus Non-biologic Treatment in Malaysia: A Retrospective Cross-Sectional Study. Drugs - real world outcomes. 2023;10(2):291-298. doi:10.1007/s40801-023-00359-1
26. Takahashi H, Iinuma S, Tsuji H, Honma M, Iizuka H. Biologics are more potent than other treatment
modalities for improvement of quality of life in psoriasis patients. J Dermatol. 2014;41(8):686-689.
doi:10.1111/1346-8138.12544
27. Norris D, Photiou L, Tacey M, et al. Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. J Dermatolog Treat. 2017;28(8):731-736. doi:10.1080/09546634.2017.1329501
28. Lambert J, Hansen JB, Sohrt A, Puig L. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatol Ther (Heidelb). 2021;11(4):1265-1275.
doi:10.1007/s13555-021-00545-5
29. Armstrong AW, Reich K, Foley P, et al. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. Am J Clin Dermatol. 2019;20(1):155-164. doi:10.1007/s40257-018-0396-z
30. Li N, Teeple A, Muser E, Lucas J, Hetherington J, Fitzgerald T. Use of the Dermatology Life Quality Index work/study domain to estimate overall work productivity loss among patients with psoriasis: an analysis based on real-world data. Clin Exp Dermatol. 2020;45(5):572-575. doi:10.1111/ced.14142
31. Puig L, Zhu B, Burge R, et al. Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Longterm Clinical Study. J Clin Aesthet Dermatol. 2020;13(10):18-22.
32. Rencz F, Gulácsi L, Péntek M, et al. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. Br J Dermatol. 2020;182(5):1167-1175. doi:10.1111/bjd.18435
33. Rencz F, Mitev AZ, Szabó Á, et al. A Rasch model analysis of two interpretations of “not relevant” responses on the Dermatology Life Quality Index (DLQI). Qual life Res an Int J Qual life Asp Treat care Rehabil. 2021;30(8):2375-2386. doi:10.1007/s11136-021-02803-7
34. Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333-337. doi:10.1111/jdv.12106
35. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10. doi:10.1007/s00403-010-1080-1
36. Pongparit K, Chularojanamontri L, Limphoka P, Silpa-Archa N, Wongpraparat C. Effectiveness of and
factors associated with clinical response to methotrexate under daily life conditions in Asian patients with psoriasis: A retrospective cohort study. J Dermatol. 2018;45(5):540-545. doi:10.1111/1346-8138.14270
37. Kimball AB, Luger T, Gottlieb A, et al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016;75(6):1156-1161.
doi:10.1016/j.jaad.2016.07.034
38. Ljosaa T, Stubhaug A, Mork C, Moum T, Wahl A. Improvement in Psoriasis Area and Severity Index
Score Predicts Improvement in Skin Pain Over Time in Patients with Psoriasis. Acta Derm Venereol.
2013;93(3):330-334. doi:10.2340/00015555-1456
39. Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1-3):163-173. doi:10.1016/j.jad.2008.06.026
40. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing Generalized Anxiety Disorder. Arch Intern Med. 2006;166(10):1092. doi:10.1001/archinte.166.10.1092
41. Allen RP, Kosinski M, Hill-Zabala CE, Calloway MO. Psychometric evaluation and tests of validity of the
Medical Outcomes Study 12-item Sleep Scale (MOS sleep). Sleep Med. 2009;10(5):531-539. doi:10.1016/j.
sleep.2008.06.003
42. Bharmal M, Payne K, Atkinson MJ, Desrosiers M-P, Morisky DE, Gemmen E. Validation of an abbreviated
Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive
medications. Health Qual Life Outcomes. 2009;7(1):36. doi:10.1186/1477-7525-7-36
Файлы
Статистика
Просмотры аннотации: 433
Просмотры XML: 1
Просмотры PDF: 239
Всего: 673